CVCapsoVision, Inc.
Price
+41%1YEnd-of-day closes, not the intraday tick.
A mixed picture: the questions disagree
A flag to check, growth steady, the market undecided.
Charts
As reported to the SEC, without any scoring.
CapsoVision, Inc. (CV) reported revenue of $3.6M in Q2 2026 (quarter ended Jun 30, 2026), up 9.9% from the same quarter a year earlier. That came with a gross margin of 51% and net loss of $7.5M. For the full year FY2025, revenue was $14M (+15% year on year) and net income −$25M. The next results filing is expected around Nov 12, 2026, the same week as a year ago.
What the company said
The company's own words from its current reports to the SEC, newest first
- Sep 28, 2026On September 28, 2026, the Company announced that AI Highlights™, its AI-assisted reading feature for the CapsoCam Plus® system, received clearance from the U.S. Food and Drug Administration on September 25, 2026.Other event · Form 8-K
- Sep 18, 2026On September 17, 2026, CapsoVision, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with certain investors (the “Purchasers”), which provides for the issuance and sale, in a registered direct offering by the Company, of an aggregate of 3,163,444 shares (the “Shares”) of its …Material agreement entered · Form 8-K
- Aug 18, 2026As previously announced, on August 13, 2026, CapsoVision, Inc. (the “Company”) entered into a Controlled Equity Offering SM Sales Agreement (the “Sales Agreement”) with Cantor Fitzgerald & Co. with respect to an at-the-market offering program under which the Company may offer and sell, from time to time at its sole …Other event · Form 8-K
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
Why these answers
Each answer with the checks it was read from. Open one for the numbers.
Conflicts between checks are named, never averaged, and thin data says so.
Medical Devices
The closest names by size in the same industry